Supported By AstraZeneca
Room 20BC, San Diego Convention Center

Program Description

In 2024, management of small cell lung cancer (SCLC) has been poised to undergo important shifts, impacting heretofore unmet needs in early-stage disease, as well as in the relapsed, advanced disease settings. These looming shifts in the standard of care leave many questions open about the optimal use of novel therapies, particularly in terms of implementing new treatments while minimizing detriments to patient safety.

This live, hybrid meeting is designed to provide participants with a current and forward-looking perspective on the management of SCLC along the disease continuum. This will be presented in the context of challenging case scenarios highlighting current unmet needs in the clinic, while addressing audience questions relating to the shifting standard of care for patients with these tumors.

Speakers

Anne Chiang MD, PhD
Program Chair
Yale School of Medicine
Medical Oncology
Associate Cancer Center Director
New Haven, CT